Cited by 351Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancerFOXO transcription factor regulation

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

PTEN Protects p53 from Mdm2 and Sensitizes Cancer Cells to Chemotherapy

Open access

Mayo, Lindsey D., Dixon, Jack E., Durden, Donald L., Tonks, Nickolas K., Donner, David B.·2002·Journal of Biological Chemistry

DOI 10.1074/jbc.m108302200

Open this paper in CoChat — free account

Abstract

The PTEN tumor suppressor protein inhibits phosphatidylinositol 3-kinase (PI3K)/Akt signaling that promotes translocation of Mdm2 into the nucleus. When restricted to the cytoplasm, Mdm2 is degraded. The ability of PTEN to inhibit the nuclear entry of Mdm2 increases the cellular content and transactivation of the p53 tumor suppressor protein. Retroviral transduction of PTEN into U87MG (PTEN null) glioblastoma cells increases p53 activity and expression of p53 target genes and induces cell cycle arrest. U87MG/PTEN glioblastoma cells are more sensitive than U87MG/PTEN null cells to death induced by etoposide, a chemotherapeutic agent that induces DNA damage. Previously, tumor suppressor proteins have been supposed to act individually to suppress cancers. Our results establish a direct connection between the activities of two major tumor suppressors and show that they act together to respond to stresses and malignancies. PTEN protects p53 from survival signals, permitting p53 to function as a guardian of the genome. By virtue of its capacity to protect p53, PTEN can sensitize tumor cells to chemotherapy that relies on p53 activity. p53 induces PTEN gene expression, and here it is shown that PTEN protects p53, indicating that a positive feedback loop may amplify the cellular response to stress, damage, and cancer.

Integrity signals

Registry

Crossref · 10.1074/jbc.m108302200

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 5,594
PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506

Show all 64 references

Research works printed but not linked: 8

Furnari, 1998, Cancer Res., 58, 5002
Chen, 1993, Mol. Cell. Biol., 13, 4107
Kubbutat, 1999, Cell Growth Diff., 10, 87
Greenblatt, 1994, Cancer Res., 54, 4855
Finlay, 1993, Mol. Cell. Biol., 13, 301
Cheney, 1998, Cancer Res., 58, 2331
Reifenberger, 1993, Cancer Res., 53, 2736
Kondo, 1995, Oncogene, 10, 2001

Sorted by citations

The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature reviews. Cancer · doi:10.1038/nrc839 · Cited by 6,155
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279
Dynamics of the p53-Mdm2 feedback loop in individual cells
Lahav, G., Rosenfeld, N., Sigal, A., Geva‐Zatorsky, N., Levine, A. J., Elowitz, M. B., & Alon, U. (2004) · Nature Genetics · doi:10.1038/ng1293 · Cited by 1,026
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
Wendel, H., de Stanchina, E., Fridman, J. S., Malina, A., Ray, S., Kogan, S. C., Cordon‐Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 956
Apoptosis and melanoma chemoresistance
Soengas, M. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1206454 · Cited by 836
The MDM2-p53 interaction.
Moll, U. M., & Petrenko, O. (2003) · PubMed · Cited by 778
Cancer associated fibroblasts (CAFs) in tumor microenvironment
Xing, F. (2010) · Frontiers in Bioscience · doi:10.2741/3613 · Cited by 682
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
Li, X., Wu, C., Chen, N., Gu, H., Yen, A., Cao, L., Wang, E., & Wang, L. (2016) · Oncotarget · doi:10.18632/oncotarget.7961 · Cited by 558
PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms
Freeman, D. J., Li, A. G., Wei, G., Li, H.-H., Kertesz, N. L., Lesche, R., Whale, A. D., Martinez-Diaz, H., Rozengurt, N., Cardiff, R. D., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00021-7 · Cited by 512
Regulating tumor suppressor genes: post-translational modifications
Chen, L., Liu, S., & Tao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0196-9 · Cited by 449
The transcriptional targets of p53 in apoptosis control
Yu, J., & Zhang, L. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.189 · Cited by 427
The PTEN, Mdm2, p53 tumor suppressor–oncoprotein network
Mayo, L. D., & Donner, D. B. (2002) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(02)02166-7 · Cited by 419
Self-citation
Untitled work
(2010) · PubMed Central
The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFβ1, PTEN, p53, and fibronectin
Baron, V. T., Adamson, E. D., Calogero, A., Ragona, G., & Mercola, D. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700896 · Cited by 345
PTEN: from pathology to biology
Sulis, M. L. (2003) · Trends in Cell Biology · doi:10.1016/s0962-8924(03)00175-2 · Cited by 342
The p53 response to DNA damage
Meek, D. W. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.03.027 · Cited by 329
Lack of PTEN sequesters CHK1 and initiates genetic instability
Puc, J. A., Keniry, M. E., Li, H. S., Pandita, T. K., Choudhury, A. D., Memeo, L., MANSUKHANI, M. M., Murty, V. V. V. S., Gaciong, Z. A., Meek, S. E. M., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.009 · Cited by 328
Role of the tumor microenvironment in tumor progression and the clinical applications (Review)
YUAN, Y., JIANG, Y.-C., SUN, C.-K., & CHEN, Q.-M. (2016) · Oncology Reports · doi:10.3892/or.2016.4660 · Cited by 320
WWP2 is an E3 ubiquitin ligase for PTEN
Maddika, S., Kavela, S., Rani, N., Palicharla, V. R., Pokorny, J. L., Sarkaria, J. N., & Chen, J. (2011) · Nature Cell Biology · doi:10.1038/ncb2240 · Cited by 306
AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy
Astle, M. V., Hannan, K. M., Ng, P. Y., Lee, R. S., George, A. J., Hsu, A. K., Haupt, Y., Hannan, R. D., & Pearson, R. B. (2012) · Oncogene · doi:10.1038/onc.2011.394 · Cited by 295
A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity
Garlich, J. R., De, P. K. R., Dey, N., Su, J. D., Peng, X., Miller, A., Murali, R., Lu, Y., Mills, G. B., Kundra, V., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-0669 · Cited by 280
Self-citation
Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma
Hu, T., Huang, C., Lin, P., Chang, H., Ger, L., Lin, Y.-W., Changchien, C., Lee, C., & Tai, M. (2003) · Cancer · doi:10.1002/cncr.11266 · Cited by 277
Posttranslational modification of MDM2.
Meek, D. W., & Knippschild, U. (2003) · PubMed · Cited by 280
Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma
Heavican, T. B., Bouska, A. C., Yu, J., Lone, W., Amador, C. C., Gong, Q., Zhang, W., Li, Y., Davé, B. J., Nairismägi, M., et al. (2019) · Blood · doi:10.1182/blood-2018-09-872549 · Cited by 278
PTEN function in normal and neoplastic growth
Chow, L. M. L., & Baker, S. J. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.11.042 · Cited by 277
The Phosphoinositide 3-Kinase Pathway in Human Cancer: Genetic Alterations and Therapeutic Implications
Arcaro, A., & Stücklin, A. G. (2007) · Current Genomics · doi:10.2174/138920207782446160 · Cited by 274
Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma
Behrooz, A. B., Talaie, Z., Jusheghani, F., Łoś, M., Klonisch, T. C., & Ghavami, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031353 · Cited by 253
Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide
Messaoudi, K., Clavreul, A., & Lagarce, F. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.011 · Cited by 238
Glioblastoma Chemoresistance: The Double Play by Microenvironment and Blood-Brain Barrier
Ros, M. D., Gregorio, V. D., Iorio, A. L., Giunti, L., Guidi, M., de Martino, M., Genitori, L., & Sardi, I. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102879 · Cited by 230
PTEN signaling in brain: neuropathology and tumorigenesis
Endersby, R., & Baker, S. J. (2008) · Oncogene · doi:10.1038/onc.2008.239 · Cited by 229
Inducible, reversible, and stable RNA interference in mammalian cells
Gupta, S., Schoer, R. A., Egan, J. E., Hannon, G. J., & Mittal, V. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306111101 · Cited by 215
Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells
Arafa, E. A., Zhu, Q., Shah, Z. I., Wani, G., Barakat, B. M., Racoma, I. O., El‐Mahdy, M. A., & Wani, A. A. (2010) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2010.10.007 · Cited by 211
The importance of p53 location: nuclear or cytoplasmic zip code?
O’Brate, A., & Giannakakou, P. (2003) · Drug Resistance Updates · doi:10.1016/j.drup.2003.10.004 · Cited by 214
The ubiquitin proteasome system in neuropathology
Lehman, N. L. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0560-x · Cited by 207
In hepatocellular carcinoma miR‐519d is up‐regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2
Fornari, F., Milazzo, M., Chieco, P., Negrini, M., Marasco, E., Capranico, G., Mantovani, V., Marinello, J., Sabbioni, S., Callegari, E., et al. (2012) · The Journal of Pathology · doi:10.1002/path.3995 · Cited by 189
Pten signaling in gliomas
Knobbe-Thomsen, C. B., Merlo, A., & Reifenberger, G. (2002) · Neuro-Oncology · doi:10.1093/neuonc/4.3.196 · Cited by 203
PTEN and myotubularin phosphatases: from 3-phosphoinositide dephosphorylation to disease
Wishart, M. J., & Dixon, J. E. (2002) · Trends in Cell Biology · doi:10.1016/s0962-8924(02)02412-1 · Cited by 183
Self-citation
Epigenetic inactivation of the p53-induced long noncoding RNA TP53 target 1 in human cancer
Díaz‐Lagares, Á., Crujeiras, A. B., López-Serra, P., Soler, M., Setién, F., Goyal, A., Sandoval, J., Hashimoto, Y., Martínez‐Cardús, A., Gómez, A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608585113 · Cited by 179
E3 ubiquitin ligases in cancer and implications for therapies
Wang, D., Ma, L., Wang, B., Liu, J., & Wei, W. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9703-z · Cited by 174
Non-genomic loss of PTEN function in cancer: not in my genes
Leslie, N. R., & Foti, M. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.12.005 · Cited by 157
PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression
Chang, C.-J., Mulholland, D. J., Valamehr, B., Mosessian, S., Sellers, W. R., & Wu, H. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00310-08 · Cited by 155
RETRACTED: Regulation of p53: intricate loops and delicate balances
Oren, M., Damalas, A., Gottlieb, T. M., Michael, D., Taplick, J., Martínez-Leal, J. F., Maya, R. B.-Y., Moas, M., Seger, R., Taya, Y., et al. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01149-8 · Cited by 150
Retracted
Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers
Ehsanian, R., Waes, C. V., & Feller, S. M. (2011) · Cell Communication and Signaling · doi:10.1186/1478-811x-9-13 · Cited by 150
Phosphorylation of Human p53 at Serine 46 Determines Promoter Selection and whether Apoptosis Is Attenuated or Amplified
Mayo, L. D., Seo, Y. R., Jackson, M. W., Smith, M. L., Guzman, J. R., Korgaonkar, C. K., & Donner, D. B. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503026200 · Cited by 149
Self-citation
Pten signaling in gliomas
Knobbe-Thomsen, C. B. (2002) · Neuro-Oncology · doi:10.1215/15228517-4-3-196 · Cited by 146
Nuclear Localization of PTEN by a Ran-dependent Mechanism Enhances Apoptosis: Involvement of an N-Terminal Nuclear Localization Domain and Multiple Nuclear Exclusion Motifs
Gil, A., Andrés‐Pons, A., Fernández, E., Valiente, M., Torres, J., Cervera, J., & Pulido, R. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-05-0380 · Cited by 143
Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation
Gravina, G. L., Festuccia, C., Marampon, F., Popov, V. M., Pestell, R. G., ZANI, B. M., & Tombolini, V. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-305 · Cited by 148
Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update
Colardo, M., Segatto, M., & Bartolomeo, S. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094899 · Cited by 141
EF24 Induces G2/M Arrest and Apoptosis in Cisplatin-resistant Human Ovarian Cancer Cells by Increasing PTEN Expression
Selvendiran, K., Tong, L., Vishwanath, S., Bratasz, A., Trigg, N. J., Kutala, V. K., Hideg, K., & Kuppusamy, P. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703796200 · Cited by 136
Dysregulation of cellular signaling by HER2 in breast cancer
Zhou, B. P. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.006 · Cited by 127
Control of cell migration: a tumour suppressor function for p53?
Roger, L., Gadéa, G., & Roux, P. (2006) · Biology of the Cell · doi:10.1042/bc20050058 · Cited by 132
Phosphatase and Tensin Homologue Deficiency in Glioblastoma Confers Resistance to Radiation and Temozolomide that Is Reversed by the Protease Inhibitor Nelfinavir
Jiang, Z., Pore, N., Cerniglia, G. J., Mick, R., Georgescu, M. M., Bernhard, E. J., Hahn, S. M., Gupta, A., & Maity, A. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3398 · Cited by 127
PTEN and phosphatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment.
Su, J. D., Mayo, L. D., Donner, D. B., & Durden, D. L. (2003) · PubMed · Cited by 121
Self-citation
PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells.
Zhou, M., Gu, L., Findley, H. W., Jiang, R., & Woods, W. G. (2003) · PubMed · Cited by 120
Potential Therapeutic Effect of Glycogen Synthase Kinase 3β Inhibition against Human Glioblastoma
Miyashita, K., Kawakami, K., Nakada, M., Mai, W., Shakoori, A., Fujisawa, H., Hayashi, Y., Hamada, J., & Minamoto, T. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0760 · Cited by 120
Why is PTEN an important tumor suppressor?
Li, L., & Ross, A. H. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21593 · Cited by 116
Phosphoinositide Signaling
Prestwich, G. D. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.03.025 · Cited by 117
Increased nuclear phosphatase and tensin homologue deleted on chromosome 10 is associated with G0-G1 in MCF-7 cells.
Ginn‐Pease, M. E., & Eng, C. (2003) · PubMed · Cited by 117
Mitochondrial Dysfunction in Pten Haplo-Insufficient Mice with Social Deficits and Repetitive Behavior: Interplay between Pten and p53
Napoli, E., Ross‐Inta, C., Wong, S., Hung, C., Fujisawa, Y., Sakaguchi, D., Angelastro, J. M., Omanska-Klusek, A., Schoenfeld, R. A., & Giulivi, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042504 · Cited by 116
NCAPG Promotes The Proliferation Of Hepatocellular Carcinoma Through PI3K/AKT Signaling
Gong, C., Ai, J., Fan, Y., Gao, J., Liu, W., Feng, Q., Liao, W., & Wu, L. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s217916 · Cited by 116
Zebrafish pten genes have overlapping and non-redundant functions in tumorigenesis and embryonic development
Faucherre, A., Taylor, G. S., Overvoorde, J., Dixon, J. E., & den Hertog, J. (2007) · Oncogene · doi:10.1038/sj.onc.1210730 · Cited by 116
Self-citation
9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-κB and p53 pathways
Guo, C., Gasparian, A. V., Zhuang, Z., Bosykh, D. A., Komar, A. A., Gudkov, A. V., & Gurova, K. V. (2009) · Oncogene · doi:10.1038/onc.2008.460 · Cited by 116
Oscillations and bistability in the stochastic model of p53 regulation
Puszyński, K., Hat, B., & Tomasz Lipniacki, B. (2008) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2008.05.039 · Cited by 116
Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma
Young, K. H., Weisenburger, D. D., Davé, B. J., Smith, L. M., Sanger, W. G., Iqbal, J., Campo, E., Delabie, J., Gascoyne, R. D., Ott, G., et al. (2007) · Blood · doi:10.1182/blood-2007-02-072082 · Cited by 111
Regulation of p53
Oren, M., Damalas, A., Gottlieb, T. M., Michael, D., Taplick, J., Martínez-Leal, J. F., Maya, R. B.-Y., Moas, M., Seger, R., Taya, Y., et al. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04669.x · Cited by 113
Myocardial Aging and Senescence: Where Have the Stem Cells Gone?
Sussman, M. A., & Anversa, P. (2004) · Annual Review of Physiology · doi:10.1146/annurev.physiol.66.032102.140723 · Cited by 105
The Cross Talk Between p53 and mTOR Pathways in Response to Physiological and Genotoxic Stresses
Cui, D., Qu, R., Liu, D., Xiong, X., Liang, T., & Zhao, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.775507 · Cited by 112
Cell Cycle Control by PTEN
Brandmaier, A., Hou, S., & Shen, W. H. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.06.004 · Cited by 105
PTEN and p53: Who will get the upper hand?
Trotman, L. C., & Pandolfi, P. P. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00022-9 · Cited by 105
PTEN: tumour suppressor, multifunctional growth regulator and more
Goberdhan, D. C. I., & WILSON, C. G. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg288 · Cited by 104
A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth
Denning, G., Jean-Joseph, B., Prince, C. Z., Durden, D. L., & Vogt, P. K. (2007) · Oncogene · doi:10.1038/sj.onc.1210175 · Cited by 102
Self-citation
It's T-ALL about Notch
Demarest, R. M., Ratti, F., & Capobianco, A. J. (2008) · Oncogene · doi:10.1038/onc.2008.222 · Cited by 101
PTEN Represses RNA Polymerase I Transcription by Disrupting the SL1 Complex
Zhang, C., Comai, L., & Johnson, D. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.16.6899-6911.2005 · Cited by 101
PTEN Regulates Mdm2 Expression through the P1 Promoter
Chang, C.-J., Freeman, D. J., & Wu, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401488200 · Cited by 100
Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner
Yan, X., Fraser, M. E., Qiu, Q., & Tsang, B. K. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.12.033 · Cited by 99
New Insights in Thyroid Cancer and p53 Family Proteins
Manzella, L., Stella, S., Pennisi, M. S., Tirrò, E., Massimino, M., Romano, C., Puma, A., Tavarelli, M., & Vigneri, P. G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061325 · Cited by 99
PTEN autoregulates its expression by stabilization of p53 in a phosphatase-independent manner
Tang, Y., & Eng, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1557 · Cited by 97
PTEN Represses RNA Polymerase III-Dependent Transcription by Targeting the TFIIIB Complex
Woiwode, A., Johnson, S. A. S., Zhong, S., Zhang, C., Roeder, R. G., Teichmann, M., & Johnson, D. L. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01912-07 · Cited by 104
Akt versus p53 in a Network of Oncogenes and Tumor Suppressor Genes Regulating Cell Survival and Death
Wee, K. B., & Aguda, B. D. (2006) · Biophysical Journal · doi:10.1529/biophysj.105.077693 · Cited by 95
Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine
Conway, J. R. W., Herrmann, D., Evans, T. J., Morton, J. P., & Timpson, P. (2018) · Gut · doi:10.1136/gutjnl-2018-316822 · Cited by 97
PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations
Li, Y., Guessous, F., Kwon, S., Kumar, M., Ibidapo, O., Fuller, L., Johnson, E., Lal, B., Hussaini, I., Bao, Y., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1963 · Cited by 95
The tumor suppressor PTEN interacts with p53 in hereditary cancer
NAKANISHI, A., Kitagishi, Y., Ogura, Y., & Matsuda, S. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2377 · Cited by 101
The TGF-β, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer
Assinder, S. J., Dong, Q., Kovačević, Ž., & Richardson, D. R. (2008) · Biochemical Journal · doi:10.1042/bj20081610 · Cited by 96
Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum
Ali, A., Farrand, L., Kim, J. Y., Byun, S., Suh, J., Lee, H. J., & Tsang, B. K. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06734.x · Cited by 90
PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas
Nakamura, J. L., Karlsson, A., Arvold, N. D., GOTTSCHALK, A. R., Pieper, R. O., Stokoe, D., & Haas-Kogan, D. A. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-004-1718-y · Cited by 90
Growth Factor-Mediated Induction of HDM2 Positively Regulates Hypoxia-Inducible Factor 1α Expression
Bárdos, J. I., Chau, N.-M., & Ashcroft, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2905-2914.2004 · Cited by 87
Restoration of wild‐type p53 function in human cancer: Relevance for tumor therapy
Bossi, G., & Sacchi, A. (2007) · Head & Neck · doi:10.1002/hed.20529 · Cited by 86
Replicative senescence revisited.
Marcotte, R., & Wang, E. (2002) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/57.7.b257 · Cited by 86
PTEN‐ and p53‐mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice
Zheng, T., Meng, X., Wang, J., Chen, X., Yin, D., Liang, Y., Song, X., Pan, S., Jiang, H., & Liu, L. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22691 · Cited by 86
Breaching barriers in glioblastoma. Part I: Molecular pathways and novel treatment approaches
Miranda, A., Blanco‐Prieto, M. J., Sousa, J., Pais, A. A. C. C., & Vitorino, C. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.07.056 · Cited by 87
Cellular and molecular mechanisms of glioblastoma malignancy: Implications in resistance and therapeutic strategies
Balça-Silva, J., Matias, D., do Carmo, A., Sarmento‐Ribeiro, A. B., Lopes, M. C., & Moura‐Neto, V. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.09.007 · Cited by 82
Oscillations by the p53-Mdm2 Feedback Loop
Lahav, G. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-09794-7_2 · Cited by 83
Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium
Minaguchi, T., Nakagawa, S., Takazawa, Y., Nei, T., Horie, K., Fujiwara, T., Osuga, Y., Yasugi, T., Kugu, K., Yano, T., et al. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.06.013 · Cited by 81
Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor
Costa, B., Bendinelli, S., Gabelloni, P., Da Pozzo, E., Daniele, S., Scatena, F., Vanacore, R., Campiglia, P., Bertamino, A., Gomez-Monterrey, I., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072281 · Cited by 79
Crosstalk between Phosphoinositide 3‐kinase/Akt signaling pathway with DNA damage response and oxidative stress in cancer
Karimian, A., Mir, S. M., Parsian, H., Refieyan, S., Mirza‐Aghazadeh‐Attari, M., Yousefi, B., & Majidinia, M. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28309 · Cited by 84
The regulation of MDM2 by multisite phosphorylation—opportunities for molecular-based intervention to target tumours?
Meek, D. W., & Hupp, T. R. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.10.005 · Cited by 76
The PTEN tumor suppressor gene and its role in lymphoma pathogenesis
Wang, X., Huang, H., & Young, K. H. (2015) · Aging · doi:10.18632/aging.100855 · Cited by 78
CRR9/CLPTM1L Regulates Cell Survival Signaling and Is Required for Ras Transformation and Lung Tumorigenesis
James, M. A., Vikis, H. G., Tate, E. R., Rymaszewski, A. L., & You, M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1617 · Cited by 77
Id-1 activates Akt-mediated Wnt signaling and p27Kip1 phosphorylation through PTEN inhibition
Lee, J.-Y., Kang, M.-B., Sh, J., Qian, T., Kim, H.-J., Kim, C., Kim, Y. D., & Kong, G. (2008) · Oncogene · doi:10.1038/onc.2008.451 · Cited by 74
Impaired p53 Expression, Function, and Nuclear Localization in Calreticulin-deficient Cells
Mesaeli, N., & Phillipson, C. S. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-04-0251 · Cited by 74

Authors: Mayo, L. D., Dixon, J. E., Durden, D. L., Tonks, N. K., & Donner, D. B.
Affiliations: Indiana University Indianapolis (US)
University of Michigan (US)
Indiana University School of Medicine (US)
Corresponding author: Donner, David B.
ORCID: Mayo, Lindsey D.
Dixon, Jack E.
Durden, Donald L.
Donner, David B.
Venue: Journal of Biological Chemistry
Publisher: Elsevier BV
Published: 2002-02
Volume: 277
Issue: 7
Pages: 5484-5489
ISSN: 0021-9258 (ISSN-L)
DOI: 10.1074/jbc.m108302200
OpenAlex: W2132279561
Cited by: 351
References: 64
Citations by year: 2026: 3 · 2025: 7 · 2024: 8 · 2023: 6 · 2022: 10 · 2021: 14 · 2020: 8 · 2019: 8 · 2018: 17 · 2017: 19 · 2016: 11 · 2015: 13 · 2014: 18 · 2013: 15 · 2012: 11
FWCI: 11.68
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
creativecommons.org/licenses/by/4.0/ (vor, 6901 d)
Locations: Journal of Biological Chemistry (publishedVersion, cc-by)
PubMed (publishedVersion)
Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › FOXO transcription factor regulation
Keywords: PTEN, p53, MDM2, tumor suppressor cooperation, glioblastoma, etoposide sensitivity, chemosensitization, PI3K/Akt signaling, nuclear translocation, cell cycle arrest, positive feedback loop, DNA damage response, U87 cells
MeSH terms: Cell Cycle, Cell Line, Cell Nucleus, Cloning, Molecular, Cytoplasm, DNA Damage, Dose-Response Relationship, Drug, Coloring Agents, Etoposide, Glioblastoma, Humans, Mutation, Neoplasms, Nuclear Proteins, Phosphoric Monoester Hydrolases, Precipitin Tests, Proto-Oncogene Proteins, Retroviridae, Tetrazolium Salts, Thiazoles, Transcription, Genetic, Transduction, Genetic, Tumor Cells, Cultured, Blotting, Western, Signal Transduction, Down-Regulation, Tumor Suppressor Protein p53, Genes, Reporter, Microscopy, Confocal, Tumor Suppressor Proteins, PTEN Phosphohydrolase, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PTEN Protects p53 from Mdm2 and Sensitizes Cancer Cells to Chemotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks